Cargando…

1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020

BACKGROUND: Multidrug-resistant (MDR) and methicillin-resistant Staphylococcus aureus (MRSA) present significant treatment challenges and can cause serious morbidity and mortality. Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced cephalosporin approved in many Eu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duncan, Leonard R, Hamed, Kamal, Smart, Jennifer, Pfaller, Michael A, Sader, Helio S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644831/ http://dx.doi.org/10.1093/ofid/ofab466.1432

Ejemplares similares

1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019
por: Duncan, Leonard R, et al.
Publicado: (2020)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

2173. Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections
por: Mendes, Rodrigo E, et al.
Publicado: (2023)

2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

1236. Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

P1240: MICROBIOME DIVERSITY IN PATIENTS WITH LYMPHOMA
por: Dlouha, Lucie, et al.
Publicado: (2023)

Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers
por: Sader, Helio S, et al.
Publicado: (2017)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

1240. Evaluation of Preoperative Staphylococcus aureus (SA) Decolonization with Nasal Iodine for Hips/Knees and Fusion Surgeries
por: Neelakanta, Anupama, et al.
Publicado: (2019)

Correction to Lancet Infect Dis 2020; 20: 1240–41
Publicado: (2020)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022)

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
por: Sharma, Amar Deep, et al.
Publicado: (2022)

Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
por: Henriksen, Anne Santerre, et al.
Publicado: (2018)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)
por: Holland, Thomas L, et al.
Publicado: (2022)

In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
por: Huband, Michael D, et al.
Publicado: (2017)

327. Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infections in European Hospitals (2010–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

1253. In Vitro Activity of Omadacycline against 7000 Bacterial Pathogens from the United States Stratified by Infection Type (2019)
por: Huband, Michael D, et al.
Publicado: (2020)

Antibiotic susceptibility and architecture of Staphylococcis aureus and Staphylococcus epidermidis biofilms
por: Coraca-Huber, DC, et al.
Publicado: (2011)

1320. In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis
por: Sader, Helio S, et al.
Publicado: (2021)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole
por: Mendes, Rodrigo E., et al.
Publicado: (2016)

2785. Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
por: Mendes, Rodrigo E, et al.
Publicado: (2023)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
por: Mendes, R. E., et al.
Publicado: (2017)

200. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against AmpC Hyperproducing Enterobacterales and P. aeruginosa Collected from United States (US) Medical Centers (2016-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)
por: Huang, David, et al.
Publicado: (2021)

PReS13-SPK-1240: New aspects on APS pathogenesis
por: Meroni, PL
Publicado: (2013)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2k0dk1vg9098nujt79nnnmq3hb